ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

计划入组 510 人 · 首次发布于 2022 年 10 月 14 日

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

计划入组 73 人 · 首次发布于 2017 年 9 月 27 日

CAR T Cells to Target GD2 for DMG

计划入组 12 人 · 首次发布于 2022 年 9 月 16 日

CCR modulator (diffuse midline Glioma)

Diffuse Midline Glioma (Dynamic Cell Therapies)

BAT-CAR T-cell therapy (diffuse midline glioma)

Harmony Biosciences

United States

Aprea Therapeutics

United States

Kura Oncology

United States

FDA Approves Modeyso as First Treatment for Recurrent H3 K27M-Mutant Diffuse Midline Glioma

Dordaviprone Shows Promise in Recurrent H3 K27M-Mutant Glioma: Updated Phase 2 Data

HealthCare Royalty Secures Modeyso Royalty Rights Following Strong Early Commercial Performance